UMIN-CTR Clinical Trial

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000014544
Receipt No. R000016917
Official scientific title of the study Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2
Date of disclosure of the study information 2014/07/14
Last modified on 2019/01/15 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2
Title of the study (Brief title) Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2
Region
Japan

Condition
Condition Non-small-cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate feasibility and efficacy of Carboplatin plus Nab-Paclitaxel in chemotherapy-naive patients with advanced non-small-cell lung cancer and a performance status of 2
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase I,II

Assessment
Primary outcomes Phase I: Dose limiting toxicity
Phase II: Progression free survival
Key secondary outcomes Phase I: Adverse event, Response rate
Phase II: Adverse event, Response rate, Overall survival

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Carboplatin plus Nab-Paclitaxel
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Pathologically confirmation of non-small-cell lung cancer
2) Stage IIIB/IV and chemo-naive non-small-cell lung cancer
3) ECOG PS 2
4) Evaluable lesions
5) Aged 20 or more
6) Adequate organ functions
7) Expected survival over 90 days
8) Written informed consent
Key exclusion criteria 1) Symptomatic brain metastasis
2) Interstitial pneumonia with usual interstitial pneumonia pattern on chest CT
3) Grade 2 or more peripheral sense neuropathy
4) With uncontrolled pleural effusion, ascites or pericardial effusion
5) Treated with palliative radiotherapy within the past two weeks
6) Active concomitant malignancy
7) Severe complication
8) HBs antigen positive
9) Previous severe drug allergy
10) Continuous systemic administration of steroid
Target sample size 33

Research contact person
Name of lead principal investigator Toshiaki Takahashi
Organization Shizuoka cancer center
Division name Division of Thoracic Oncology
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
TEL (+81)055-989-5222
Email t.takahashi@scchr.jp

Public contact
Name of contact person Kazuhisa Nakashima
Organization Shizuoka cancer center
Division name Division of Thoracic Oncology
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
TEL (+81)055-989-5222
Homepage URL
Email ka.nakashima@scchr.jp

Sponsor
Institute Shizuoka cancer center
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 静岡県立静岡がんセンター(静岡県)
和歌山県立医科大学病院(和歌山県)
倉敷中央病院(岡山県)
広島市立広島市民病院(広島県)

Other administrative information
Date of disclosure of the study information
2014 Year 07 Month 14 Day

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2014 Year 06 Month 07 Day
Anticipated trial start date
2014 Year 07 Month 14 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2014 Year 07 Month 13 Day
Last modified on
2019 Year 01 Month 15 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016917